The monoaminergic neurotransmitters dopamine, noradrenaline, and serotonin are pivotal actors of the interplay between the nervous and the immune system due to their ability of binding to cell-receptors of both systems, crucially regulating their function within the central nervous system and the periphery. As monoamines are dysfunctional in many neurological and psychiatric diseases, they have been successfully used as pharmacological targets. Multiple sclerosis (MS) is one of the best examples of neurological disease caused by an altered interaction between the nervous and immune system and emerging evidence supports a dysregulation of monoaminergic systems in the pathogenesis of MS, secondary to both inflammation-induced reduction of monoamines’ synthesis and structural damage to monoaminergic pathways within the brain. Here we review the evidence for monoamines being key mediators of neuroimmune interaction, affecting MS pathogenesis and course. Moreover, we discuss how the reduction/dysfunction of monoamines in MS may contribute to some clinical features typical of the disease, particularly fatigue and depression. Finally, we summarize different drugs targeting monoamines that are currently under evaluation for their potential efficacy to treat MS, as well as to alleviate fatigue and depression in MS.

The distinct roles of monoamines in multiple sclerosis: A bridge between the immune and nervous systems? / T. Carandini, M. Cercignani, D. Galimberti, E. Scarpini, M. Bozzali. - In: BRAIN BEHAVIOR AND IMMUNITY. - ISSN 0889-1591. - 94:(2021 May), pp. 381-391. [10.1016/j.bbi.2021.02.030]

The distinct roles of monoamines in multiple sclerosis: A bridge between the immune and nervous systems?

T. Carandini
Primo
;
D. Galimberti;E. Scarpini
Penultimo
;
2021

Abstract

The monoaminergic neurotransmitters dopamine, noradrenaline, and serotonin are pivotal actors of the interplay between the nervous and the immune system due to their ability of binding to cell-receptors of both systems, crucially regulating their function within the central nervous system and the periphery. As monoamines are dysfunctional in many neurological and psychiatric diseases, they have been successfully used as pharmacological targets. Multiple sclerosis (MS) is one of the best examples of neurological disease caused by an altered interaction between the nervous and immune system and emerging evidence supports a dysregulation of monoaminergic systems in the pathogenesis of MS, secondary to both inflammation-induced reduction of monoamines’ synthesis and structural damage to monoaminergic pathways within the brain. Here we review the evidence for monoamines being key mediators of neuroimmune interaction, affecting MS pathogenesis and course. Moreover, we discuss how the reduction/dysfunction of monoamines in MS may contribute to some clinical features typical of the disease, particularly fatigue and depression. Finally, we summarize different drugs targeting monoamines that are currently under evaluation for their potential efficacy to treat MS, as well as to alleviate fatigue and depression in MS.
Depression; Dopamine; Fatigue; Monoamines; Multiple Sclerosis; Neuroimmunology; Noradrenaline; Serotonin; Dopamine; Humans; Neurotransmitter Agents; Norepinephrine; Serotonin; Multiple Sclerosis
Settore BIO/13 - Biologia Applicata
Settore MED/26 - Neurologia
mag-2021
apr-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
18.CarandiniT.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 2.83 MB
Formato Adobe PDF
2.83 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/902164
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 21
social impact